ArticleBritish journal of pharmacology2015
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.
Article in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 62 citations in OpenAlex.
- Emerging cannabinoids differ in behavioral safety margins in mice: a comparative hazard proximity analysis of locomotor suppression and catalepsy-like immobility.Forensic toxicology · 2026Article
- Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound-Indication Matching and Precision Neurotherapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multidimensional analysis of social withdrawal in the sub-chronic phencyclidine rat model for schizophrenia.Psychopharmacology · 2026Article
- The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.Current topics in behavioral neurosciences · 2026Review
- Tetrahydrocannabivarin is Not Tetrahydrocannabinol.Cannabis and cannabinoid research · 2025Review
- Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.Handbook of experimental pharmacology · 2025Review
- In the weeds: A comprehensive review of cannabis; its chemical complexity, biosynthesis, and healing abilities.Toxicology reports · 2024Review
- The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders.Biomolecules · 2024Review
- [Cannabis use and cannabis use disorders].Der Nervenarzt · 2024Review
- The Use of Compounds Derived fromInternational journal of molecular sciences · 2024Review
- The Leu/ValJournal of chemical information and modeling · 2023Article
- Decoding the Postulated Entourage Effect of MedicinalBiomedicines · 2023Review
- How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases.Therapeutic advances in chronic disease · 2023Review
- Cannabinoids: Therapeutic Use in Clinical Practice.International journal of molecular sciences · 2022Review
- Molecular Targets of Cannabinoids Associated with Depression.Current medicinal chemistry · 2022Review
- Impact of specific serotonin receptor modulation on restricted repetitive behaviors.Frontiers in behavioral neuroscience · 2022Review
- Biosynthesis and synthetic biology of psychoactive natural products.Chemical Society reviews · 2021Review
- Review
- Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThis study aimed to address the questions of whether Δ(9)-tetrahydrocannabivarin (THCV) can (i) enhance activation of 5-HT1 A receptors in vitro and (ii) induce any apparent 5-HT₁A receptor-mediated antipsychotic effects in vivo. EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT₁A receptors in membranes obtained from rat brainstem or human 5-HT₁A CHO cells, using [(35)S]-GTPγS and 8-[(3)H]-OH-DPAT binding assays. In vivo studies investigated whether THCV induces signs of 5-HT₁A receptor-mediated antipsychotic effects in rats. KEY
resultsTHCV (i) potently, albeit partially, displaced 8-[(3) H]-OH-DPAT from specific binding sites in rat brainstem membranes; (ii) at 100 nM, significantly enhanced 8-OH-DPAT-induced activation of receptors in these membranes; (iii) produced concentration-related increases in 8-[(3)H]-OH-DPAT binding to specific sites in membranes of human 5-HT₁A receptor-transfected CHO cells; and (iv) at 100 nM, significantly enhanced 8-OH-DPAT-induced activation of these human 5-HT₁A receptors. In phencyclidine-treated rats, THCV, like clozapine (i) reduced stereotyped behaviour; (ii) decreased time spent immobile in the forced swim test; and (iii) normalized hyperlocomotor activity, social behaviour and cognitive performance. Some of these effects were counteracted by the 5-HT₁A receptor antagonist, WAY100635, or could be reproduced by the CB₁ antagonist, AM251. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that THCV can enhance 5-HT₁A receptor activation, and that some of its apparent antipsychotic effects may depend on this enhancement. We conclude that THCV has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.